GX-03

COMBINATION_PRODUCT2 trials

Sponsors

Turn Therapeutics

Conditions

Atopic DermatitisCovid19EczemaEczema Atopic Dermatitis

Phase 2

Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.

CompletedNCT04951349

Turn TherapeuticsCovid19

Start: 2021-01-21End: 2021-05-30Updated: 2021-07-06

A Study to Assess the Efficacy of GX-03 in Moderate to Severe Eczema (Atopic Dermatitis)

RecruitingNCT07355075

Turn TherapeuticsAtopic Dermatitis, Eczema, Eczema Atopic Dermatitis

Start: 2025-07-11End: 2026-06-30Target: 100Updated: 2026-01-22